The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has
constituted a determinant resource to control the COVID-19 pandemic. Since the beginning …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019
prompted scientific, medical, and biotech communities to investigate infection-and vaccine …

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …

In late February, 2023, some sublineages of the SARS-CoV-2 omicron XBB variant
harbouring the F486P substitution in the spike protein (eg, XBB. 1.5 and XBB. 1.9) …

Background In late 2022, the SARS-CoV-2 omicron (B. 1.1. 529) BA. 5 sublineage
accounted for most of the sequenced viral genomes worldwide. Bivalent mRNA vaccines …

Background Bivalent BA. 1 booster vaccines were offered to adults aged 50 years or older
and clinically vulnerable people as part of the 2022 autumn COVID-19 booster vaccination …

Background Limited evidence is available on the additional protection conferred by second
mRNA vaccine boosters against severe COVID-19 caused by omicron BA. 5 infection, and …

Importance A correlation between antibody levels and risk of infection has been
demonstrated for the wild-type, Alpha, and Delta SARS-COV-2 variants. High rates of …

Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …

Since emergence of the initial SARS-CoV-2 BA. 1, BA. 2 and BA. 5 variants, Omicron has
diversified substantially. Antigenic characterization of these new variants is important to …